Wedbush Has Optimistic Outlook of BCRX Q3 Earnings

Key Points

• Wedbush analysts have increased their Q3 2025 EPS estimate for BioCryst Pharmaceuticals to $0.07 per share, up from $0.04, maintaining an "Outperform" rating with a price target of $18.00.
• In its latest quarterly earnings report, BioCryst Pharmaceuticals surpassed expectations by reporting a $0.15 EPS and 49.5% revenue growth year-over-year, with total revenue of $163.35 million.
• The company has a consensus rating of "Buy" among analysts, with an average price target of $16.70, reflecting positive sentiment regarding its future performance.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush increased their Q3 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, August 4th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $0.07 per share for the quarter, up from their previous forecast of $0.04. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.04 EPS and FY2028 earnings at $1.05 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. During the same period in the previous year, the firm posted ($0.06) EPS. The firm's quarterly revenue was up 49.5% on a year-over-year basis.

A number of other research analysts have also recently weighed in on BCRX. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Trading Down 0.6%

BCRX traded down $0.05 on Wednesday, reaching $8.30. The stock had a trading volume of 1,823,000 shares, compared to its average volume of 3,745,884. BioCryst Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $11.31. The business's 50-day moving average price is $9.32 and its two-hundred day moving average price is $8.76. The company has a market cap of $1.74 billion, a P/E ratio of -46.11, a price-to-earnings-growth ratio of 1.89 and a beta of 1.10.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $33,000. GAMMA Investing LLC boosted its holdings in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $62,000. Finally, Family Legacy Financial Solutions LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $72,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.